Literature DB >> 29417228

Comparison of long-term clinical outcomes between endoscopic and surgical resection for early-stage adenocarcinoma of the esophagogastric junction.

Hyun Ju Kim1,2, Hyunsoo Chung3,4, Sung Kwan Shin5, Hyoung-Il Kim6, Jun Chul Park7, Sang Kil Lee7, Woo Jin Hyung6, Yong Chan Lee7, Sung Hoon Noh6.   

Abstract

BACKGROUND: The aim of this study was to analyze long-term clinical and oncologic outcomes in patients with early-stage adenocarcinoma of the esophagogastric junction (AEG) managed with either endoscopic resection (ER) or surgery.
METHODS: The inclusion criteria were AEG, meeting classic or expanded indications for ER of early gastric cancer, and complete resection. A total of 66 patients with Siewert type II AEG were included (ER group, n = 38; vs. surgery group, n = 28).
RESULTS: The mean age of the ER group was greater than that of the surgery group (mean ± SD, 66.9 ± 9.7 vs. 58.5 ± 10.4 years, respectively; p = 0.001). Compared to the ER group, macroscopically flat or depressed-type lesions were more common (47.4 vs. 89.3%; p = 0.001), and mean lesion size was larger in the surgery group (13.3 ± 8.4 vs. 18.6 ± 11.0 mm; p = 0.039). One intensive care unit admission and subsequent surgery-related death occurred in the surgery group (1/28 vs. 0/38 in the ER group; p = 0.424). During follow-up, recurrence was detected in both groups (4/38 vs. 1/28; p = 0.385). Overall survival and 5-year disease-free survival did not differ between the groups (93.3 vs. 92.9%; p  = 0.282 and 88.0 vs. 100.0%; p = 0.066).
CONCLUSIONS: Once complete resection is achieved in patients with AEG who met the expanded criteria for endoscopic submucosal dissection of gastric cancer, there was no significant difference in clinical outcomes between ER and surgery.

Entities:  

Keywords:  Adenocarcinoma; Early stage; Endoscopic resection; Esophagogastric junction; Surgical resection

Mesh:

Year:  2018        PMID: 29417228     DOI: 10.1007/s00464-018-6076-5

Source DB:  PubMed          Journal:  Surg Endosc        ISSN: 0930-2794            Impact factor:   4.584


  16 in total

1.  [Survival rate of proximal and total gastrectomy in treatment of esophagogastric junction adenocarcinoma (Siewert II( Types)].

Authors:  Chao Nai; Zhen Liu; Xiao Lian; Shushang Liu; Man Guo; Shuao Xiao; Jinqiang Liu; Xuewen Yang; Hongwei Zhang
Journal:  Zhonghua Wei Chang Wai Ke Za Zhi       Date:  2016-02

2.  Superficial adenocarcinoma of the esophagogastric junction: long-term results of endoscopic submucosal dissection.

Authors:  Kingo Hirasawa; Atsushi Kokawa; Hiroyuki Oka; Sei Yahara; Takeshi Sasaki; Akinori Nozawa; Katsuaki Tanaka
Journal:  Gastrointest Endosc       Date:  2010-11       Impact factor: 9.427

3.  Japanese classification of gastric carcinoma: 3rd English edition.

Authors: 
Journal:  Gastric Cancer       Date:  2011-06       Impact factor: 7.370

4.  Japanese gastric cancer treatment guidelines 2010 (ver. 3).

Authors: 
Journal:  Gastric Cancer       Date:  2011-06       Impact factor: 7.370

5.  Assessment of open versus laparoscopy-assisted gastrectomy in lymph node-positive early gastric cancer: a retrospective cohort analysis.

Authors:  Ji Yeong An; Geon-Ung Heo; Jae-Ho Cheong; Woo Jin Hyung; Seung Ho Choi; Sung Hoon Noh
Journal:  J Surg Oncol       Date:  2010-07-01       Impact factor: 3.454

Review 6.  Clinical outcomes of endoscopic submucosal dissection for early stage esophagogastric junction cancer: a systematic review and meta-analysis.

Authors:  Chan Hyuk Park; Eun Hye Kim; Ha Yan Kim; Yun Ho Roh; Yong Chan Lee
Journal:  Dig Liver Dis       Date:  2014-11-12       Impact factor: 4.088

7.  Safety, efficacy, and long-term outcomes for endoscopic submucosal dissection of early esophagogastric junction cancer.

Authors:  Masami Omae; Junko Fujisaki; Yusuke Horiuchi; Natsuko Yoshizawa; Yasumasa Matsuo; Manabu Kubota; Takanori Suganuma; Kazuhisa Okada; Akiyoshi Ishiyama; Toshiaki Hirasawa; Yorimasa Yamamoto; Tomohiro Tsuchida; Etsuo Hoshino; Masahiro Igarashi
Journal:  Gastric Cancer       Date:  2012-06-13       Impact factor: 7.370

8.  Long-term outcome of endoscopic resection of superficial adenocarcinoma of the esophagogastric junction.

Authors:  Masayoshi Yamada; Ichiro Oda; Satoru Nonaka; Haruhisha Suzuki; Shigetaka Yoshinaga; Hirokazu Taniguchi; Shigeki Sekine; Ryoji Kushima; Yutaka Saito; Takuji Gotoda
Journal:  Endoscopy       Date:  2013-11-28       Impact factor: 10.093

9.  Quality of life after gastrectomy for adenocarcinoma: a prospective cohort study.

Authors:  Paul J Karanicolas; Dennis Graham; Mithat Gönen; Vivian E Strong; Murray F Brennan; Daniel G Coit
Journal:  Ann Surg       Date:  2013-06       Impact factor: 12.969

Review 10.  Proximal Gastrectomy for Gastric Cancer.

Authors:  Do Hyun Jung; Sang-Hoon Ahn; Do Joong Park; Hyung-Ho Kim
Journal:  J Gastric Cancer       Date:  2015-06-30       Impact factor: 3.720

View more
  4 in total

1.  Comparison of Long-Term Outcomes of Endoscopic Submucosal Dissection and Surgery for Early Gastric Cancer: a Systematic Review and Meta-analysis.

Authors:  Lihu Gu; Parikshit A Khadaroo; Liangliang Chen; Xinlong Li; Hepan Zhu; Xin Zhong; Junhai Pan; Manman Chen
Journal:  J Gastrointest Surg       Date:  2019-05-06       Impact factor: 3.452

2.  Endoscopic submucosal dissection for early esophagogastric junction adenocarcinomas: a systematic review.

Authors:  Paul Doumbe-Mandengue; Anna Pellat; Benoit Terris; Frédéric Beuvon; Mahaut Leconte; Anthony Dohan; Stanislas Chaussade; Romain Coriat; Maximilien Barret
Journal:  Ann Gastroenterol       Date:  2022-05-12

3.  Endoscopic resection versus esophagectomy for early esophageal cancer: a meta-analysis.

Authors:  Hao Zheng; Ningning Kang; Yunlong Huang; Yuan Zhao; Renquan Zhang
Journal:  Transl Cancer Res       Date:  2021-06       Impact factor: 1.241

4.  Predictors of Lymph Node Metastasis in Siewert Type II T1 Adenocarcinoma of the Esophagogastric Junction: A Population-Based Study.

Authors:  Liubo Chen; Kejun Tang; Sihan Wang; Dongdong Chen; Kefeng Ding
Journal:  Cancer Control       Date:  2021 Jan-Dec       Impact factor: 3.302

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.